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Adenoviral gene therapy using the death receptor ligand TRAIL as the therapeutic transgene can be safely administered via
intraprostatic injection but has not been evaluated for eﬃcacy in patients. Here we investigated the eﬃcacy of adenoviral TRAIL
genetherapyinamodelofcastrationresistantprostatecancerandfoundthatintratumoralinjectionscansigniﬁcantlydelaytumor
growth but cannot eliminate established lesions. We hypothesized that an underlying cause is ineﬃcient adenoviral delivery. Using
the LNCaP progression model of prostate cancer we show that surface CAR expression decreases with increasing tumorigenicity
and that castration resistant C4-2b cells were more diﬃcult to transduce with adenovirus than castration sensitive LNCaP cells.
Many genes, including CAR, are epigenetically silenced during transformation but a new class of chemotherapeutic agents, known
as histone deacetylase inhibitors (HDACi), can reverse this process. We demonstrate that HDACi restore CAR expression and
infectivity in C4-2b cells and enhance caspase activation in response to infection with a TRAIL adenovirus. We also show that
in cells with high surface CAR expression, HDACi further enhance transgene expression from the CMV promoter. Thus HDACi
have multiple beneﬁcial eﬀects, which may enhance not only viral but also non-viral gene therapy of castration resistant prostate
cancer.
1.Introduction
Epigenetic alterations, such as aberrant activity of histone
deacetylases, are frequently observed in malignancies. Acet-
ylation of histones is associated with less condensed chro-
matin and a transcriptionally active gene status, while dea-
cetylation is associated with transcriptional silencing. His-
tone deacetylase inhibitors (HDACiS) were originally found
to reverse the malignant phenotype of transformed cells
and have subsequently been developed as a new group
of chemotherapeutic agents. HDACi can aﬀect numerous
signaling pathways to inhibit growth or angiogenesis and
induce apoptosis or senescence [1, 2]. Using two HDACi
under evaluation for the treatment of prostate cancer, we
previously demonstrated that both romidepsin (also known
as depsipeptide) and MS-275 enhanced the in vitro eﬃcacy
of adenoviral TRAIL gene therapy in castration-sensitive
LNCaP prostate cancer cells [3]. This eﬀect was selective for
the malignant cells as primary cultures of prostate epithelial
cells were not adversely aﬀected [3].
TRAIL gene therapy has been evaluated for safety in
prostate cancer patients with locally conﬁned disease sched-
uled for prostatectomy [4]. Although eﬃcacy was not
evaluated as part of the trial, evidence of TUNEL staining
in prostates injected with AdTRAIL indicated that DNA
fragmentation, a hallmark of apoptosis, had occurred [4].
While these results are promising, novel therapies are still
desperately needed for patients with aggressive disease. We
therefore set out to evaluate the eﬃcacy of TRAIL gene
therapy against the aggressive, castration-resistant LNCaP-
derived C4-2b cell line and to investigate potential beneﬁts
of therapy with HDACi. Our results suggest that HDACi2 Prostate Cancer
have multiple eﬀects that can be beneﬁcial for the treatment
of aggressive prostate cancers, particularly when used in
combination with TRAIL gene therapy.
2.MaterialsandMethods
2.1. Cell Culture. LNCaP and its sublines C4-2 and C4-2b
were grown in T-medium containing 5% heat-inactivated
FBS and supplements [5], while 22Rv1 cells were cultured
in RPMI1640 supplemented with 10% heat-inactivated FBS
and nonessential amino acids. Heat-inactivated FBS was
purchased from Hyclone, Logan, UT. Cell cultures were
maintained at 37◦Ci na5 %C O 2 atmosphere and were
cultured in Primaria plasticware (Falcon, Bedford, MA).
2.2. Histone Deacetylase Inhibitors. MS-275 was purchased
from Calbiochem (San Diego, CA). The Romidepsin was
generously provided by Celgene Corporation and the
National Cancer Institute, NIH.
2.3. Adenoviral Transduction. The adenoviral vectors have
previously been described [3, 6]. Constructs were titered
by counting GFP-positive cells, and titers were expressed
as infectious units/mL (IU/mL). Cells were plated at 2 ×
105/well in 12-well plates. The next day cells were infected
in growth medium at the indicated IU/cell. HDACi, if any,
were given simultaneously. Fluorescence microscopy was
performed with a Zeiss Axioscope 200 equipped with an
MR5 camera.
2.4. Caspase-3/7 Assay. Cells were plated at 1 × 104/well
in a 96-well plate on the day prior to treatment initiation.
HDACi, if any, were given simultaneously. The Apo-ONE
Homogeneous Caspase 3/7 Assay (Promega, Madison, WI)
was performed 24 hours after infection/treatment initiation
according to the manufacturer’s instructions. Plates were
read using a FluoStar plate reader (BMG Labtechnologies
Inc.,Durham,NC)withemissionandexcitationwavelengths
of 485nm and 520nm, respectively.
2.5. Transfection. Cells were seeded at 6 × 104/well on a 24-
well plate and allowed to attach overnight. Transfections
were performed with Lipofectamine according to the man-
ufacturers instructions using 0.4µgD N Aa n d2µLt r a n s f e c -
tion reagent/well. The CMV-luciferase plasmid (pCMV.luc)
was kindly provided by Dr. Omar Moussa, MUSC. Biolumi-
nescence was quantiﬁed 48 hours after transfection using an
IVIS Xenogen 200.
2.6.FlowCytometry. ForGFPanalysis,cellsweretrypsinized,
pelleted, and resuspended in PBS prior to ﬂow cytometry.
To measure surface CAR expression, cells were rinsed with
PBS, removed from the plate with Cell Stripper (Mediatech)
at room temperature, and washed twice. All washes and
incubations were done in 2% FBS in PBS. Cell pellets
were resuspended in 50µL primary CAR antibody (1:250,
UpstateBiotechnologies,cloneRmcB,catno.05–644)oriso-
type antibody (BD Pharmingen mouse IgG1, cat no. 554121)
and incubated for 1h at room temperature. After washing
twice, cell pellets were resuspended in secondary Ab (1:100,
Biomeda Phycoprobe R-PE anti-mouse IgGH+L, cat no.
p63) for 30min at room temperature in the dark. Cells
were washed twice prior to ﬂow cytometry analysis. Flow
cytometry was performed in the MUSC core facility on a
FACSCalibur (Becton Dickenson, Bedford, MA) and data
analyzed with the FlowJo version 8.8.6 software.
2.7. Animal Experiments and Statistical Analysis. All animal
studies were performed under a protocol approved by the
InstitutionalAnimalCareandUseCommitteeoftheMedical
University of South Carolina. Subconﬂuent C4-2b cells were
trypsinized, pelleted, and resuspended to a concentration of
2 × 107 cells/mL in PBS. A volume of 100µL( 2× 106 cells)
was injected into the ﬂanks of mice. Established tumors were
injected with 1 × 109 infectious units (IUs) of adenovirus
on day 0, day 3, and day 6. Tumor size was monitored with
a digital caliper and volume calculated using the formula:
tumor volume = width2 × length × 0.52. Animals were
sacriﬁced 14 days after treatment initiation.
Linear regression was used to estimate the slope (ex-
pected change in tumor volume associated with one-day
time increase) for each tumor. Group comparisons of the
estimated slope values were performed using the Wilcoxon
rank-sum test, a nonparametric alternative of the t-test,
whichisrobusttodeviationsfromthenormalityassumption.
The P values for this test were computed using exact
calculationsduetothesmallsamplesizes.Analyseshavebeen
performed using SAS version 9 (SAS Institute, Cary, NC).
3. Results and Discussion
3.1. Adenoviral TRAIL Gene Therapy Delays the Growth
of Established Castration-Resistant Tumors. Adenoviral gene
therapy using TRAIL as the therapeutic transgene has
recently entered the clinic. Intraprostatic injection of the
AdTRAIL virus was found to be safe, but eﬃcacy remains
to be determined [4]. While localized prostate cancer can
be eﬀectively managed and/or treated as evidenced by 5-year
survival rates approaching 100%, more advanced castration-
resistant disease remains incurable. Since novel treatment
options for castration-resistant prostate cancer are urgently
needed, we evaluated the eﬃcacy of adenoviral TRAIL gene
therapy in C4-2b cells, the most aggressive cell line of
the LNCaP progression model [5]. The LNCaP progression
model mimics phenotypic and genotypic changes observed
in human prostate cancer as it progresses from a castration-
sensitive to castration-resistant phenotype and has therefore
been widely used for in vitro and in vivo studies of the
disease. Previous in vitro studies from our laboratory have
shown that soluble, recombinant TRAIL has little eﬀect
on the viability of C4-2b cells, whereas an adenovirus-
expressing membrane TRAIL (AdTRAIL) induced cell death
in a concentration-dependent manner [6]. To determine the
eﬃcacy of AdTRAIL in vivo, we subcutaneously injected
2 million C4-2b cells and initiated treatment with AdGFP
or AdTRAIL when tumors were established. As shown inProstate Cancer 3
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Figure 1: Eﬃcacy of AdTRAIL in subcutaneous C4-2b xenografts.
Male mice were subcutaneously injected with 2 million C4-2b
cells. After tumor establishment, mice received three intratumoral
injectionsof1×109 IUofAdGFPorAdTRAILevery3days(arrows).
Data shown are from 6 tumors/group (P = 0.015).
Figure 1, AdTRAIL signiﬁcantly reduced the rate of tumor
growth in vivo (P-value for the slopes between AdGFP-
and AdTRAIL-treated mice was 0.015). Although the results
were statistically signiﬁcant, tumor growth began to recover
after treatment termination, and tumor eradication was not
achieved in any animal. It is not clear whether expression of
TRAIL in our model inhibited tumor growth, which then
resumed when transgene expression declined or whether
TRAIL induced apoptosis in a subset of cells, while non-
transduced cells continued to proliferate. Either eﬀect would
result in a delay in tumor outgrowth. A recent study with
human prostate cancer tissue found that stromal TRAIL
expression is associated with better disease outcome, which
supportstheideaofcontrollingtumoroutgrowth[7].Onthe
other hand, it is well known that in vivo rates of adenoviral
transduction rates are low, and it is likely that only a small
fraction of the tumor cells were virally transduced. Thus,
adenoviral TRAIL gene therapy would likely be enhanced
by combination therapies that improve transduction and/or
increase bystander activity of the TRAIL transgene.
3.2. Progressive Loss of CAR Surface Expression in the LNCaP
Progression Model Is Associated with Reduced Adenoviral
Transduction. Eﬃcacy of adenoviral gene therapy depends
in part on the ability of the virus to transduce cells.
Adenovirus enters cells by binding to a cell surface protein
called coxsackie and adenovirus receptor (CAR) [8, 9].
In human prostate tissue, a decrease in CAR expression
correlated with increasing tumor grade [10]. We therefore
asked whether a decrease in CAR is also observed in the
LNCaP progression model. Using ﬂow cytometry to measure
surface CAR, we found that compared to LNCaP cells, C4-2
and C4-2b cells had reduced their surface CAR expression by
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Figure 2: CAR expression and adenoviral infectivity. (a) Surface
CAR expression was determined by ﬂow cytometry. Mean ﬂuores-
cence of cells stained with CAR antibody minus mean ﬂuorescence
of cells stained with the isotype control was determined. The
average ± SD was calculated, and signiﬁcance was determined
using the student t-test. ∗P<0.05, ∗∗P<0.0005. (b) Adenoviral
infectivity was determined by the expression of GFP 48 hours
after transduction. All data shown are the mean ± SD from 3
independently performed experiments.
approximately 50% and 70%, respectively (Figure 2(a)). The
decrease in surface CAR expression also resulted in poorer
adenoviral transduction eﬃciency. As shown in Figure 2(b),
followingexposureto100MOI,only30%ofC4-2bcellswere
transduced by adenovirus as determined by GFP transgene
expression. In LNCaP cells, this level of infectivity was
achieved at approximately 10MOI, indicating that a 10-
fold higher concentration of adenovirus was required to
transduce C4-2b cells. These results demonstrate that the
decrease in CAR expression observed in human prostate
tumors also occurs in the LNCaP progression model.
Although CAR was originally discovered as a viral receptor,4 Prostate Cancer
it has subsequently been identiﬁed as an adhesion protein
[11]. Thus, the decrease in CAR expression in parallel with
increasing tumorigenicity may at least in part contribute to
the metastatic properties of C4-2 and C4-2b cell lines, since
a decrease in adhesion is a prerequisite for dissemination of
tumor cells to distant sites.
3.3. Treatment with Histone Deacetylase Inhibitors Restores
Surface CAR Expression and Enhances Adenoviral Transduc-
tion Eﬃciency as well as TRAIL-Mediated Caspase Activity.
The decrease of CAR expression has previously been shown
tooccurbyepigeneticmodulationoftheCARgenepromoter
[12]. Inhibition of histone deacetylation but not DNA
methylation restored CAR expression in several urogen-
ital cancer cell lines [12]. Numerous histone deacetylase
inhibitors (HDACiS) are being explored in clinical trials
as single agents or in combination therapies [13]. These
chemotherapeutic agents function, at least in part, to reverse
epigenetic changes that contribute to the development and
progression of malignancies. We have previously shown that
the HDACi romidepsin and MS-275, which are both under
investigation for their therapeutic potential against prostate
cancer, can selectively enhance AdTRAIL gene therapy in
castration-sensitive LNCaP cells and that an increase in CAR
expression contributed to this eﬀect [3]. We therefore next
asked how HDACi aﬀect CAR expression and adenoviral
infectivity in the more aggressive, castration-resistant cell
line C4-2b. As shown in Figure 3, both romidepsin and MS-
275 enhance surface CAR expression in C4-2b cells to levels
that were comparable to parental LNCaP cells.
Next, we investigated the biological consequences of
HDACi-mediated restoration of CAR expression. As shown
in Figure 4, treatment with HDACi increased adenoviral
infectivity in C4-2b cells to levels that were comparable
to those in LNCaP cells. We also investigated the eﬀect
of HDACi on caspase-3/7 activation following transduction
with AdTRAIL. As shown in Figure 5, although AdTRAIL
alonedidresultinincreasedcaspase-3/7activitycomparedto
untreatedor control-infected(AdGFP) C4-2b cells, theeﬀect
was greatly enhanced by treatment with HDACi.
Restoration of CAR expression by HDACi could improve
the eﬃcacy of gene therapy not only by increasing uptake of
adenovirus during the initial delivery but also by promoting
viral spread throughout the tumor when conditionally
replicative adenovirus is used. In addition, HDACi have
been shown to synergize with TRAIL; thus, in addition
to improved adenoviral transgene expression, a higher
percentage of tumor cells may be killed due to bystander
activity. Lastly, by increasing CAR expression, cancer cells
may become more adhesive and less prone to metastasize to
distant sites.
3.4. Histone Deacetylase Inhibitors Enhance CMV-Mediated
Gene Expression. Next, we asked whether the increased
eﬃcacy of HDACi treatment on adenoviral GFP transgene
expression was solely due to increased CAR expression.
To address this question, we chose 22Rv1 cells, which
are highly tumorigenic but nonmetastatic [14]. These cells
express high levels of surface CAR (mean ﬂuorescence
CAR antibody minus mean ﬂuorescence isotype control
antibody: 24.20 ±5.76, n = 4)andareeasilytransducedwith
adenovirus (Figure 6(a)). Interestingly, while HDACi did
not further increase surface CAR expression (Figure 6(b)),
adenoviral transgene expression was strongly enhanced as
shownbyﬂuorescentmicroscopyofGFPlevels(Figure 7(a)).
Since GFP expression in the adenoviral vector is under
control of the CMV promoter, we wondered whether HDACi
enhanced promoter activity. To determine the eﬀect of
HDACi on CMV promoter activity, we transfected a CMV-
drivenluciferasereportergeneinto22Rv1cellsandmeasured
luminescence. Our results indicated that both romidepsin
and MS-275 enhance luciferase expression from the CMV
promoter (Figure 7(b)). Similar results were obtained in C4-
2bcells(datanotshown).WealsoanalyzedtheGFPintensity
in LNCaP and C4-2b cells following transduction with
AdGFP. Although C4-2b cells are not as readily transduced
with adenovirus (see Figure 2(b)), the intensity of GFP
expression among GFP-positive cells was similar to LNCaP
cells(Figure 8).HDACisigniﬁcantlyenhancedGFPintensity,
suggesting that this eﬀect may be due to stimulation of
the CMV promoter and thus GFP transgene expression
(Figure 8). In agreement with our results, VanOosten et al.
previously reported that romidepsin enhanced CMV pro-
moter activity in Du145 prostate cancer cells [15]. HDACi-
mediated enhancement of transgene expression from the
CMV promoter would be beneﬁcial not only for viral gene
therapybutalsofornonviralapproaches.Forexample,recent
studies demonstrated that HDACi enhanced the eﬃcacy of a
CMV-driven DNA vaccine and may also improve polymer-
mediated gene delivery [16, 17]. Interestingly, HDACi
inhibited gene expression from a prostate-speciﬁc promoter,
indicating that combination of these drugs with tissue-
speciﬁc promoters needs to be carefully evaluated [18]. In
cases when HDACi inhibit tissue-speciﬁc promoter activity,
the human telomerase promoter, which has been used for
transcriptional targeting of transformed cells, may be a
suitable choice [19].
4. Conclusions
We propose that maximum eﬃcacy against advanced pros-
tate cancer can be safely achieved by combining HDACi
with TRAIL gene therapy using conditionally replicative
adenovirus (CRAd). CRAd vectors propagate under certain
conditionssubsequentlykillingtheinfectedcellandinfecting
neighboring cells. The resulting lateral spread of the virus is
thought to increase the eﬃcacy of adenoviral gene therapy.
However, lateral spread to malignant cells would be impaired
if surface CAR expression has been epigenetically silenced.
Thus, HDACi therapy when used in combination with
CRAd TRAIL gene therapy can be envisioned to (1) restore
surface CAR levels and facilitate viral transduction and
spread among cells with previously reduced CAR expression,
(2) through positive inﬂuence on CMV promoter activity
enhance TRAIL transgene expression, and (3) by negative
inﬂuence of genes associated with apoptosis resistanceProstate Cancer 5
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Figure 3: The eﬀect of HDACi on surface CAR expression in C4-2b cells. Surface CAR expression was determined by ﬂow cytometry in
LNCaPcells(L =redlines),C4-2bcells(C =greenlines),andC4-2bcellsinthepresenceofHDACi(CdorCm =bluelines).Cdindicatesthat
100ng/mL romidepsin was used, whereas Cm indicates a dose of 1µM MS-275. (c) Graphical representation of the data. RD = romidepsin.
would boost bystander activity of the TRAIL transgene. An
additional beneﬁt of HDACi therapy would be that the
restoration of CAR as well as other epigenetically silenced
genes such as E-cadherin that is involved in maintenance of
adhesion may decrease the risk of metastasis. An important
next step will be to evaluate HDACi/AdTRAIL combination
therapy in an in vivo model. Based on the eﬀects observed in
vitro, it is likely that combination therapy results in increased
eﬃcacy, yet due to the pleiotropic eﬀects of HDACi, a pri-
mary mechanism of action may be diﬃcult to discern. With
regard to prostate cancer, it would be interesting to evaluate
systemic HDACi therapy in combination with intraprostatic
injections of AdTRAIL in orthotopically implanted C4-2b
cells to determine whether this therapeutic strategy has the
potential to diminish dissemination of advanced, castration-
resistant prostate cancer.6 Prostate Cancer
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Figure 4: Analysis of GFP expression by ﬂuorescence microscopy and quantiﬁcation by ﬂow cytometry. LNCaP (a) and C4-2b (b, c)
were plated overnight and exposed to 10MOI AdGFP in the absence (a, b) or presence of (c) 10µM MS-275. Fluorescent images were
collected using identical camera settings 48hrs after viral transduction (magniﬁcation = 200x). (d) Quantiﬁcation of GFP-positive cells by
ﬂow cytometry 24hrs after viral transduction in the absence or presence of 100ng/mL romidepsin or 10µM MS-275. Data shown are the
mean ± SD from three experiments.
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Figure 5: Caspase-3/7 activity in C4-2b cells. C4-2b cells were left uninfected or were transduced with 10MOI of AdGFP or AdTRAIL in
the absence or presence of MS-275 (b) or 10ng/mL romidepsin (a). Caspase-3/7 activity was determined at 48 hours. Data shown are the
mean ± SD of an assay performed in triplicate.Prostate Cancer 7
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Figure 6: Adenoviral infectivity and surface expression in 22Rv1
cells. (a) 22Rv1 cells were transduced with increasing amounts of
AdGFP. The presence of GFP-positive cells was quantiﬁed by ﬂow
cytometry at 48hrs after transduction. Data shown are the mean ±
SD of an assay performed in duplicate. (b) Surface CAR expression
was determined by ﬂow cytometry (green = isotype, blue = anti-
CAR, untreated cells, and red = anti-CAR in cells treated with
10 µM MS-275).
5. Main Take-Home Message
Histonedeacetylaseinhibitorshavemultiplebeneﬁcialeﬀects
including improved adenoviral gene therapy by restoration
of CAR expression on aggressive tumor cells and increased
transgene expression from the CMV promoter, which may
enhance not only viral but also nonviral gene therapy.
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